Larimar Net Income Per Share from 2010 to 2024
| LRMR Stock | USD 7.76 0.09 1.15% |
Net Loss | First Reported 2010-12-31 | Previous Quarter (0.84) | Current Value (0.88) | Quarterly Volatility 13.28026075 |
Check Larimar Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Larimar Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 472.6 K, Selling General Administrative of 8.9 M or Other Operating Expenses of 38.2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.57. Larimar financial statements analysis is a perfect complement when working with Larimar Therapeutics Valuation or Volatility modules.
Larimar | Net Income Per Share |
Latest Larimar Therapeutics' Net Income Per Share Growth Pattern
Below is the plot of the Net Income Per Share of Larimar Therapeutics over the last few years. It is Larimar Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Larimar Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Income Per Share | 10 Years Trend |
|
Net Income Per Share |
| Timeline |
Larimar Net Income Per Share Regression Statistics
| Arithmetic Mean | (18.09) | |
| Coefficient Of Variation | (73.41) | |
| Mean Deviation | 12.21 | |
| Median | (22.85) | |
| Standard Deviation | 13.28 | |
| Sample Variance | 176.37 | |
| Range | 32.4753 | |
| R-Value | 0.92 | |
| Mean Square Error | 29.50 | |
| R-Squared | 0.84 | |
| Slope | 2.73 | |
| Total Sum of Squares | 2,469 |
Larimar Net Income Per Share History
About Larimar Therapeutics Financial Statements
Larimar Therapeutics shareholders use historical fundamental indicators, such as Net Income Per Share, to determine how well the company is positioned to perform in the future. Although Larimar Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Larimar Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Larimar Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | (0.84) | (0.88) |
Pair Trading with Larimar Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Larimar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Larimar Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Larimar Stock
| 0.63 | VALN | Valneva SE ADR | PairCorr |
| 0.77 | DYAI | Dyadic International | PairCorr |
| 0.76 | ERNA | Eterna Therapeutics | PairCorr |
Moving against Larimar Stock
| 0.67 | GILD | Gilead Sciences | PairCorr |
| 0.66 | BMY | Bristol Myers Squibb | PairCorr |
| 0.65 | A | Agilent Technologies Earnings Call Next Week | PairCorr |
| 0.46 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.45 | GNFT | Genfit | PairCorr |
The ability to find closely correlated positions to Larimar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Larimar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Larimar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Larimar Therapeutics to buy it.
The correlation of Larimar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Larimar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Larimar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Larimar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Larimar Stock Analysis
When running Larimar Therapeutics' price analysis, check to measure Larimar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Larimar Therapeutics is operating at the current time. Most of Larimar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Larimar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Larimar Therapeutics' price. Additionally, you may evaluate how the addition of Larimar Therapeutics to your portfolios can decrease your overall portfolio volatility.